ArticleCureus2024
Expression of β-Catenin in Salivary Gland Tumors.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSalivary gland tumors are an important group of neoplasms in the head and neck region. This study aims to assess the significance of β-catenin expression in both benign and malignant salivary gland tumors. MATERIALS AND
methodsWe included 80 reported cases of benign and malignant salivary gland tumors and employed β-catenin stain on tumor blocks. A consultant histopathologist interpreted the β-catenin expression, and a score of 0, 1, 2, 3 was given based on intensity as completely absent, mild, moderate, or intense. Intracellular localization of β-catenin stain was interpreted as the percentage of membranous, cytoplasmic, or nuclear expression.
resultsExpression in benign and malignant classes of salivary gland tumors differs in intensity and localization. The benign category of tumors exhibited primarily membranous expression, and all cases of Warthin tumor showed intense membranous expression (p ≤ 0.05). Malignant tumors manifested chiefly cytoplasmic expression, and among the malignant category, adenoid cystic carcinoma showed intense cytoplasmic localization (p ≤ 0.05). None of the tumors showed nuclear expression.
conclusionDecreased membranous and increased cytoplasmic expression could predict malignant behavior and invasive potential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.